RxDoctor Payments Data

Daniel Grob, MD

Family Medicine · Pittsburgh, PANPI 1740254309

Payments from drug & device makers

$861in general payments, 2019–2025

Across 29 payments — averaging $29.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inari Medical, Inc.$179
  • Medtronic$125
  • AbbVie$124
  • Sanofi-aventis U.S. LLC$103
  • Johnson & Johnson$84
  • Pfizer$57
  • plus $188 from 7 others

What the payments were for

  • Food & beverage$81495%
  • Gifts$475%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$861 in reported general payments places this provider in the 65th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$228,314
Medicare patients
601
Services billed
4,887

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban304$214,285
XareltoRivaroxaban136$95,743
JardianceEmpagliflozin109$76,809
OzempicSemaglutide27$41,695
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$35,652
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr32$16,935
TrulicityDulaglutide18$15,671
EntrestoSacubitril/Valsartan23$12,295
Atorvastatin Calcium889$10,022
Breo ElliptaFluticasone/Vilanterol17$7,760
Levothyroxine Sodium540$6,497
Fluticasone-SalmeterolFluticasone Propion/Salmeterol19$5,114
Potassium Chloride164$4,538
Metoprolol Succinate238$4,375
Tamsulosin Hcl258$4,346

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$57$214,285304 claims
Johnson & JohnsonXarelto$84$95,743136 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$47$60,34883 claims
AbbVieSynthroid$124$2,56462 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →